Insider buying last 90 days
No open-market insider purchases were filed for GKOS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Glaukos moves this week on record Q3 2026 results, with net sales of $211 million, up 58% year-over-year, a return to profitability, and raised full-year sales guidance, which together drove its inclusion in the S&P 400 and subsequent ETF inflows that altered the shareholder base. The company also shared a November 2026 investor presentation citing 30% 2025 growth projections, and announced an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a tri-specific biologic for retinal diseases including wet age-related macular degeneration. A director's sale of 2,500 shares worth $632,500 was also disclosed via Form 4 filing.
The stock closes at $238.74, up 6.4%, sitting well above both its 50-day average of $179.44 and 200-day average of $144.82, with the 50-day above the 200-day. The GekkoIndex reads 46.3, placing it in the Neutral zone. Price stands 17.1% above Gekko Fair Value of $203.94.
Over the next 20 trading days, the next earnings date falls on 16 February 2027, outside this window. Thirty-day options activity shows 2 unusual signals, with put premium of $4,360,135 against zero call premium. Seasonality over 5 years shows an average 0% return across the next 20 trading days, with gains in 1 of those years. Consensus among 11 analysts stands at 10 buy, 1 hold, with a consensus target of $242.46.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Glaukos scores 2 supportive, 1 mixed and 3 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed3 headwinds
Above 50 and 200-day
Close $245.72 is above the 50-day ($184.62) and 200-day ($147.26) averages, and the 50-day is above the 200-day.
See the chart50.3, Neutral
Reading 50.3 is in the Neutral zone.
See the GekkoIndex18.3% above
Price is 18.3% above Gekko Fair Value (more than 5% above).
See fair valueLeans bearish
Last 30 days: 2 unusual options signals.
See smart moneyReports in 93 days
Next report Feb 16, 2027, 93 days away — outside a typical 20-trading-day hold.
See earnings−1.6% on average
From this point in the calendar, the next 20 trading days averaged −1.6% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Glaukos closed at $245.72 on Nov 13, 2026, +165.3% over the past year, inside a 52-week range of $87.32 to $255.19.
Use the left and right arrow keys to read daily values.
Put GKOS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Glaukos develops medical devices and pharmaceutical products for eye conditions, with particular attention to glaucoma along with corneal and retinal disorders. It is best recognized for its micro-bypass stent line, including iStent, iStent inject, and iStent inject W, small devices implanted during cataract surgery to help fluid drain from the eye and ease mild-to-moderate open-angle glaucoma. Beyond these established products, the company is advancing iStent Infinite, a three-stent option meant to be used on its own for harder-to-treat glaucoma cases, and iDose TR, an implant built on its micro-scale technology that delivers medication directly to the eye over time.
Glaukos reaches physicians and patients through its own sales force as well as outside distributors, with sales spanning both domestic and international markets.
The company was founded in 1998 and is based in San Clemente, California. Its shares trade on the NYSE under the ticker GKOS.
Glaukos’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.3, in the Neutral zone, up 5.1 points over five sessions.
Up 5.1 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +0.9% | +5.0% | ||
| Accumulation | 164 | +1.0% | +4.8% | ||
| Neutral (current zone) | 448 | +0.9% | +2.5% | ||
| Distribution | 48 | +0.8% | −0.5% | ||
| Selling | 8 | Too few readings yet | |||
Average GKOS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Glaukos trades 18.3% above Gekko Fair Value of $207.76, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Glaukos shares are worth, recalculated every trading day.
$207.76
Gekko Fair Value, Nov 14, 2026
18.3% Overvalued
At the end of Aug 2026 the price was 3.1% below the estimate.
No open-market insider purchases were filed for Glaukos, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for GKOS in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in GKOS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Glaukos has been buying back its own shares.
From company filings.
2signals, 0% of the flagged premium in calls.
Latest: Bearish flow on Nov 6, $3.87M in unusual premium.
1of the funds Gekko tracks holds GKOS.
Glaukos reports on Feb 16, 2027, after the close (93 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 16, 2027
Expected after the close, 93 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 28, 2026 | $0.47 est −$0.10 | $211.0M est $168.0M | +33.8% |
| Jul 29, 2026 | −$0.14 est −$0.28 | $185.6M est $150.9M | +11.4% |
| Apr 29, 2026 | −$0.18 est −$0.28 | $150.6M est $137.0M | +20.1% |
| Feb 17, 2026 | −$0.28 est −$0.22 | $143.1M est $136.4M | +10.5% |
| Oct 29, 2025 | −$0.16 est −$0.27 | $133.5M est $129.5M | +12.9% |
| Jul 30, 2025 | −$0.24 est −$0.26 | $124.1M est $122.4M | −8.2% |
| Apr 30, 2025 | −$0.22 est −$0.35 | $106.7M est $102.8M | −11.0% |
| Feb 20, 2025 | −$0.40 est −$0.39 | $105.5M est $101.0M | −21.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Glaukos is $242.46, −1.3% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | UBS | $241 | −1.9% |
| Oct 30 | H.C. Wainwright | $248 | +0.9% |
| Oct 29 | Citi | $247 | +0.5% |
| Oct 29 | Stifel Nicolaus | $225 | −8.4% |
| Oct 29 | Needham | $251 | +2.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Glaukos averaged −1.6% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.1% | 1 of 5 |
| Next 10 trading days | −2.1% | 1 of 5 |
| Next 15 trading days | −2.9% | 1 of 5 |
| Next 20 trading days | −1.6% | 1 of 5 |
| Next 30 trading days | +6.0% | 3 of 5 |
For scale, GKOS’s typical 20-trading-day move in either direction is about 8.2%.
Glaukos’s market cap is $14.55B and revenue of $690.3M over the last twelve months.
Coverage of Glaukos this week reads neutral: 4 positive, 5 neutral and 2 negative headlines.
Glaukos’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Glaukos’s market cap is $14.55B at the Nov 13, 2026 close of $245.72, with 59.20M shares outstanding.
The consensus analyst 12-month price target for Glaukos is $242.46, −1.3% from the last close. Of the 11 firms that rated the stock in the last 90 days, 10 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Glaukos is overvalued: the Nov 13, 2026 close of $245.72 is 18.3% above Gekko Fair Value of $207.76. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Glaukos is expected to report on Feb 16, 2027, after the market closes (93 days away). Analysts expect earnings of $0.50 per share on revenue of $233.3M. Glaukos beat the earnings estimate in 6 of its last 8 reports, moving 16.2% on average across the report.
Glaukos’s 52-week high is $255.19 and its 52-week low is $87.32; it closed at $245.72 on Nov 13, 2026, +165.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 6 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 3 as headwinds (fair value, smart money and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in Glaukos over the last 30 days, with $0 of flagged premium in calls and $4.36M in puts. The latest, bearish flow, was on Nov 6, 2026 with $3.87M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.